Abiraterone and Increased Survival in Metastatic Prostate Cancer
Open accessThe DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index; 17 of the 40 sources its claims cite were checked for support.
Abstract
BACKGROUND: Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy. METHODS: We randomly assigned, in a 2:1 ratio, 1195 patients who had previously received docetaxel to receive 5 mg of prednisone twice daily with either 1000 mg of abiraterone acetate (797 patients) or placebo (398 patients). The primary end point was overall survival. The secondary end points included time to prostate-specific antigen (PSA) progression (elevation in the PSA level according to prespecified criteria), progression-free survival according to radiologic findings based on prespecified criteria, and the PSA response rate. RESULTS: After a median follow-up of 12.8 months, overall survival was longer in the abiraterone acetate-prednisone group than in the placebo-prednisone group (14.8 months vs. 10.9 months; hazard ratio, 0.65; 95% confidence interval, 0.54 to 0.77; P<0.001). Data were unblinded at the interim analysis, since these results exceeded the preplanned criteria for study termination. All secondary end points, including time to PSA progression (10.2 vs. 6.6 months; P<0.001), progression-free survival (5.6 months vs. 3.6 months; P<0.001), and PSA response rate (29% vs. 6%, P<0.001), favored the treatment group. Mineralocorticoid-related adverse events, including fluid retention, hypertension, and hypokalemia, were more frequently reported in the abiraterone acetate-prednisone group than in the placebo-prednisone group. CONCLUSIONS: The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy. (Funded by Cougar Biotechnology; COU-AA-301 ClinicalTrials.gov number, NCT00638690.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 7 Not checked · 36 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A unique molecular alteration described in castration-resistant prostate cancer is the up-regulation of androgen biosynthesis enzymes, leading to an increase in intratumoral androgen concentrations, which can exceed the levels measured in the blood.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [7] matched to “Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance” (2004) source
- Partly supportedcites [8] matched to “Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer” (2006) sourceExperimental — accuracy not yet measured
The Abstract and Discussion (page numbers unavailable) report increased expression of androgen-metabolism genes in androgen-independent prostate cancer and propose enhanced intracellular conversion of adrenal androgens as a mechanism for substantial tissue androgen levels. The paper does not state that intratumoral androgen concentrations exceed blood levels; its tissue comparison is with normal or nonneoplastic prostate. (LLM, conf=0.88)
- Partly supportedcites [9] matched to “Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth” (2008) sourceExperimental — accuracy not yet measured
The Results report up-regulated transcripts for androgen-biosynthesis enzymes in castration-resistant metastases and say tumor testosterone concentrations exceeded equivalent concentrations in the patients’ serum. But the Discussion says the processes sustaining intratumoral androgens have yet to be determined and proposes enzyme modulation as a possible mechanism; it does not establish that the up-regulation caused the higher concentrations. No page number is available in our copy. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Treatment with abiraterone acetate did not appear to increase the risk of metabolic changes or symptoms associated with chronic androgen deprivation.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Could not verifycites [42] matched to “Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer” (2010) sourceExperimental — accuracy not yet measured
The Methods passage describes GnRH agonists, orchiectomy, and oral antiandrogens, but does not identify abiraterone acetate as a treatment studied. The Results and Discussion address diabetes and cardiovascular outcomes for those treatments, not metabolic changes or symptoms during abiraterone treatment. Searches for “abiraterone acetate” and the claimed metabolic changes and symptoms found no passage addressing that specific claim. (LLM, conf=0.77)
- Could not verifycites [43] matched to “Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology” (2010) sourceExperimental — accuracy not yet measured
The 'Adverse Effects of ADT' section describes metabolic changes associated with androgen-deprivation therapy generally, but does not assess abiraterone acetate. Searches for 'abiraterone acetate' and 'symptoms associated with chronic androgen deprivation' found no passage addressing whether abiraterone increases those risks. (LLM, conf=0.76)
- Not checked yetcites [44] matched to “Management of Complications of Prostate Cancer Treatment” (2008) source
- Not checked yetcites [45] matched to “Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer” (2004) source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These results show that continued androgen-receptor signaling contributes to disease progression”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Not checked yetcites [2] matched to “Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis” (2005) source
- Supportedcites [10] matched to “Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?” (2009) source
The Abstract of the Attard et al. (2009) Cancer Cell preview states that 'clinical data from abiraterone acetate and MDV-3100 confirm continued androgen receptor (AR) addiction in a significant proportion of castration-resistant prostate cancers,' and the Main Text adds that 'the growth of the majority of cancer cells in many patients with cancers recurring after castration remains dependent on the AR signaling axis,' with nuclear AR expression persisting in metastases and AR transcriptional activity described as 'required for prostate cancer progression' (Hormone-Driven Oncogenesis). The conclusion reiterates that a significant proportion of CRPC finds AR signaling 'a hard habit to break.' This covers the claim's substance — persistent AR signaling contributing to progression in metastatic CRPC — though the source phrases it as addiction/persistence in a significant proportion rather than in all patients. (LLM, conf=0.88)
- Not checked yetcites [31] matched to “Novel Therapeutic Strategies for Castration Resistant Prostate Cancer: Inhibition of Persistent Androgen Production and Androgen Receptor Mediated Signaling” (2011) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In phase 1–2 trials, treatment with abiraterone acetate, either as a single agent or in combination with low-dose glucocorticoids such as prednisone, resulted in significant antitumor activity among both patients with progressing castration-resistant prostate cancer who had not received chemotherapy and those who had received chemotherapy.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Abstract > CONCLUSIONS
What the sources say
- Partly supportedcites [15] matched to “Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer” (2009) sourceExperimental — accuracy not yet measured
The Abstract Patients and Methods (p.1) and Introduction state this phase I/II trial enrolled castrate, chemotherapy-naive CRPC patients only, and the PATIENTS AND METHODS > Patients section explicitly excludes 'Patients who had previously received cytotoxic chemotherapy or a radiopharmaceutical'; the antitumor activity figures (≥50% PSA decline in 67% of 42, RECIST partial responses in 9/24, Abstract Results) therefore apply solely to the chemotherapy-naive population. The low-dose glucocorticoid component is supported in that the study prospectively added dexamethasone 0.5 mg/d at progression and reversed resistance in 33% of patients (Abstract Results; Discussion). What this source does not support is the post-chemotherapy arm of the claim: the Discussion mentions only that a phase III study of abiraterone plus prednisone in docetaxel-treated patients 'is now being evaluated,' with no results reported here. (LLM, conf=0.85)
- Supportedcites [16] matched to “Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids” (2010) source
In the body of this correspondence (section 'Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids'), the authors open by summarising the three multicenter phase I/II studies of abiraterone acetate in CRPC (chemotherapy-naive Ryan et al, and the post-docetaxel Reid et al and Danila et al studies listed in their References) and state that their prechemotherapy data 'confirmed the significant antitumor activity of abiraterone acetate' (radiologic regression, PSA and circulating tumour cell decreases), that the combination with low-dose corticosteroids (dexamethasone/prednisone) gave 'durable secondary tumor responses... in 25% of patients', and close by affirming 'the significant and durable antitumor activity and the satisfactory safety profile of abiraterone acetate at 1,000 mg daily'. Low-dose prednisone is explicitly named. This source is correspondence reporting/summarising those trials rather than a primary trial report, but it states every element attributed to it here. (LLM, conf=0.82)
- Partly supportedcites [17] matched to “Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven” (2008) sourceExperimental — accuracy not yet measured
Our copy is a single phase I trial, and it confirms significant antitumor activity (PSA declines ≥30%/≥50% in 66%/57% of 21 patients, RECIST partial responses in 5 of 8) in chemotherapy-naive CRPC (Antitumor Activity section), with low-dose dexamethasone 0.5 mg/d added at progression reinducing sensitivity in 4 of 15 patients (Reversal of Resistance section). However, the post-chemotherapy arm and the phase II results are not reported here: the Discussion (B2 C1 C2) states only that these findings 'have led to the phase II evaluation... in both chemotherapy-naïve and docetaxel-treated patients... data from this evaluation will be reported soon,' and the Patients section explicitly excluded men previously treated with chemotherapy. Prednisone is not the glucocorticoid used in this paper (dexamethasone was), so the 'phase 1-2 trials... both chemotherapy-naive and post-chemotherapy' scope is not carried by this source. (LLM, conf=0.78)
- Supportedcites [18] matched to “Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer” (2010) source
Our copy covers every element of the summary sentence. The Abstract and Results describe this phase II trial of abiraterone acetate 1,000 mg daily with low-dose prednisone 5 mg twice daily in 58 men with progressive metastatic CRPC after docetaxel failure, reporting significant antitumor activity (confirmed ≥ 50% PSA decline in 36%, partial responses in 4/22 RECIST-evaluable patients, ECOG improvement in 28%). The Introduction states that 'Significant antitumor effects were seen in patients with progressive CRPC who had not received prior chemotherapy' (citing the phase I trial, Attard 2008, and the phase II chemo-naive AA-plus-prednisone study, Ryan 2009) and that 'In a separate trial, we showed significant antitumor effects of abiraterone acetate (AA) monotherapy in this patient group' (post-docetaxel, Reid/Danila), i.e. activity with AA alone as well as with low-dose steroid, in both chemotherapy-naive and post-chemotherapy settings. The Discussion likewise frames this as 'the second trial showing the activity of AA in patients ... who have progressed on chemotherapy.' (LLM, conf=0.85)
- Partly supportedcites [19] matched to “Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate” (2010) sourceExperimental — accuracy not yet measured
Our copy directly supports the trial/patient-population part: the Conclusion (p. 1) and DISCUSSION (p. 5) state that abiraterone acetate 1,000 mg had significant antitumor activity in post-docetaxel CRPC (≥50% PSA declines in 51%, with radiologic, symptomatic and CTC support), and the INTRODUCTION (p. 2) plus DISCUSSION (p. 6) report the authors' own phase I and phase II pre-docetaxel (chemotherapy-naïve) studies as showing abiraterone 'well tolerated and active'. What our copy does not support is the efficacy attribution to a glucocorticoid combination: low-dose glucocorticoids (and eplerenone) appear only as management of mineralocorticoid-excess toxicities (Treatment and Procedures, p. 3; Safety, p. 5; DISCUSSION, p. 6), the trial itself was single-agent abiraterone, and prednisone co-administration is mentioned only as the design of the subsequent phase III trial (DISCUSSION, p. 5), not as a phase 1-2 activity result. (LLM, conf=0.78)
- Partly supportedcites [20] matched to “Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy” (2010) sourceExperimental — accuracy not yet measured
Ryan et al. (2010) supports only part of the sentence: the DISCUSSION (p. 1) states 'Abiraterone acetate has significant activity in patients with CRPC, as evidenced by a PSA response rate of 58% in this phase I trial,' and RESULTS/Efficacy report confirmed ≥50% PSA declines in 55%-58% of men with chemotherapy-naïve progressive CRPC, including 47% of those with prior ketoconazole. However, this is a single-agent phase I dose-escalation trial only — 'Prior chemotherapy for prostate cancer was not allowed' (Major Eligibility Criteria), and the DISCUSSION states the exclusion of prior-chemotherapy patients was intentional, with 'ongoing studies...evaluating abiraterone in patients with both chemotherapy-refractory and chemotherapy-naïve CRPC,' so the post-chemotherapy activity attributed here is not from this paper. Glucocorticoids were also not part of the tested regimen: prednisone/corticosteroids were used reactively to manage mineralocorticoid toxicity, and the authors only 'suggest that a low dose of a corticosteroid, such as prednisone, be administered with abiraterone acetate in future studies'; the DISCUSSION notes 'the impact of concurrent prednisone on response proportion and durability...is not known.' (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The safety profile observed in the group of patients who received abiraterone acetate was similar to that observed in earlier clinical studies.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Partly supportedcites [15] matched to “Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer” (2009) sourceExperimental — accuracy not yet measured
Our copy details the safety profile of the 1,000-mg abiraterone acetate group in RESULTS > Safety Profile (secondary mineralocorticoid excess: hypokalemia 88%, hypertension 40%, fluid overload 31%, managed with eplerenone; grade 3 transaminase elevation in 2 patients; grade 1 headaches/joint aches) and calls it 'effective, well-tolerated' in the DISCUSSION, so the first half of the claim is grounded. However, no passage states that this profile was 'similar to that observed in earlier clinical studies'; the only cross-study safety remarks compare abiraterone with ketoconazole trials (grade >=3 toxicities in up to 30% of patients, all requiring hydrocortisone) and explicitly caution that 'it is difficult to make any comparisons.' The prior abiraterone phase I experience is referenced (ref 15) as having identified the 1,000-mg dose, not as a matched safety comparison. The comparative/similarity element is therefore unsupported by our copy. (LLM, conf=0.68)
- Partly supportedcites [17] matched to “Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven” (2008) sourceExperimental — accuracy not yet measured
Our copy documents this trial's own safety profile (Safety and Tolerability: dose escalation to 2,000 mg achieved, no treatment-related grade 3 or 4 toxicities, hypertension/hypokalemia/edema controlled with eplerenone; DISCUSSION: toxicities predominantly due to secondary mineralocorticoid excess), and the INTRODUCTION notes that first-in-man studies reported abiraterone acetate was safe when given daily for 12 days to men with prostate cancer. However, no passage compares the two or states the profiles were similar; the only 'similar' statement in the paper is of hypertension incidence across dose levels within this study, and the DISCUSSION frames this as 'the first study to demonstrate that selective and continuous inhibition of CYP17 is safe', with the earlier clinical experience being short-course dosing in noncastrate men. The comparative element of the claim ('similar to that observed in earlier clinical studies') is therefore not supported by this source. (LLM, conf=0.65)
- Partly supportedcites [20] matched to “Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy” (2010) sourceExperimental — accuracy not yet measured
Ryan et al. (2010) describe their own safety findings as acceptable and consistent with expected CYP17 inhibition (DISCUSSION: 'The adverse event and steroid endocrine profiles were consistent with anticipated outcomes of selective CYP17 inhibition'; well tolerated through 1,000 mg/d with no MTD and no toxicity difference by prior ketoconazole exposure, DISCUSSION). However, the only external comparison our copy makes is to a CONCURRENT study, not to earlier clinical studies: RESULTS (Dose Escalation) states 'These findings paralleled a concurrent study with abiraterone acetate.' The claim's framing of similarity to 'earlier clinical studies' is therefore not supported by this source. (LLM, conf=0.68)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
23 more claims · 3 with their cited sources checked
Create a free account to see all 50 claims and to verify the 23 references still open.
- It may state two separate claims as one. 10
- The quote only partly states this claim. 3
- Probably not a substantial claim. 11
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Abiraterone acetate is an orally active prodrug of abiraterone, a potent P450c17 inhibitor (316) indicated for treatment of castration-resistant prostate cancer (317, 318).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [317]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although improvements in clinical outcomes have been observed with novel therapies [20–31], their approval has resulted in uncertainties on optimal treatment sequencing, and utilization of these treatments is limited, demonstrating the need for improved real-world treatment practices.”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [20]
In the citing paper
“Abiraterone is a potent CYP17A1 inhibitor that efficiently inhibits testosterone production120 and is used to treat prostate cancer.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [120]
In the citing paper
“Additionally, androgen biosynthesis from C21 precursors can be reduced by CYP17A1 inhibition with abiraterone as successfully applied for the treatment of CRPC (Attard et al., 2008, de Bono et al., 2011, James et al., 2017).”
From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as de Bono et al., 2011
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647 · cited 2×
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 2×
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Self-citationSipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 3×
“Bone pain 194 (25) 42 (5) 2 (<1) 110 (28) 25 (6) 4 (1)”
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241 · cited 1×
“Fluid retention and edema 241 (31) 16 (2) 2 (<1) 88 (22) 4 (1) 0”
Self-citationde Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,182 · cited 2×
“Nausea 233 (30) 12 (2) 1 (<1) 124 (32) 10 (3) 0”
Self-citationDevelopment of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases
Daut, R. L., Cleeland, C. S., & Flanery, R. C. (1983) · Pain · doi:10.1016/0304-3959(83)90143-4 · Cited by 1,562
Cited by
Items 301–400 of 1,010
The androgen/androgen receptor axis in prostate cancer
Bluemn, E. G., & Nelson, P. S. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835105b3 · Cited by 161
Kiess, A. P., Minn, I., Vaidyanathan, G., Hobbs, R. F., Josefsson, A., Shen, C., Brummet, M., Chen, Y., Choi, J., Koumarianou, E., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.174300 · Cited by 137
“Systemic agents including docetaxel, enzalutamide, and abiraterone have provided small survival benefits (3,4).”
BackgroundCastration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment
Sridhar, S. S., Freedland, S. J., Gleave, M. E., Higano, C. S., Mulders, P., Parker, C. C., Sartor, O. A., & Fred Saad, C. (2013) · European Urology · doi:10.1016/j.eururo.2013.08.008 · Cited by 152
“Patients received AA 1000 mg daily on an empty stomach plus prednisone 5 mg twice daily (AA/prednisone) or prednisone alone [12].”
Nouruzi, S., Ganguli, D., Tabrizian, N., Kobelev, M., Sivak, O., Namekawa, T., Thaper, D., Baca, S. C., Freedman, M. L., Aguda, A. H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29963-5 · Cited by 151
Adverse effects of androgen‐deprivation therapy in prostate cancer and their management
Rhee, H., Gunter, J. H., Heathcote, P. S., Ho, K. K. Y., Stricker, P. D., Corcoran, N. M., & Nelson, C. C. (2014) · British Journal of Urology · doi:10.1111/bju.12964 · Cited by 147
Mostaghel, E. A., Solomon, K. R., Pelton, K., Freeman, M. R., & Montgomery, R. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030062 · Cited by 136
Ex vivo culture of human prostate tissue and drug development
Centenera, M. M., Raj, G. V., Knudsen, K. E., Tilley, W. D., & Butler, L. M. (2013) · Nature Reviews Urology · doi:10.1038/nrurol.2013.126 · Cited by 149
Schweizer, M. T., Zhou, X. C., Wang, H., Bassi, S., Carducci, M. A., Eisenberger, M. A., & Antonarakis, E. S. (2014) · European Urology · doi:10.1016/j.eururo.2014.01.018 · Cited by 136
“Abiraterone was initially approved in the postdocetaxel window; however, more recently it has also been approved for prechemotherapy use [8,9].”
BackgroundPodrazil, M., Horváth, R., Becht, É., Rožková, D., Bílková, P., Sochorová, K., Hromádková, H., Kayserová, J., Vávrová, K., Lašťovička, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4145 · Cited by 142
“Apart from taxanes, three additional agents that directly target tumor cells have recently been reported to increase the median OS in mCRPC patients as well: enzalutamide, an anti-androgen therapy [7]; abiraterone - an inhibitor of testosterone synthesis [8]; and Alpharadin, an alpha-emitter that targets bone metastas…”
Crona, D. J., & Whang, Y. E. (2017) · Cancers · doi:10.3390/cancers9060067 · Cited by 160
“The double-blinded, placebo-controlled COU-AA-301 trial was conducted in chemotherapy-pretreated mCRPC patients (n = 1195) [6].”
MethodFitzpatrick, J. M., & de Wit, R. (2013) · European Urology · doi:10.1016/j.eururo.2013.07.022 · Cited by 154
“This activity is the rationale for androgen-directed therapies such as abiraterone and enzalutamide, which have shown survival benefits in castration-resistant PCa (CRPC) [17,18].”
BackgroundGuinney, J., Wang, T., Laajala, T. D., Winner, K. K., Bare, J. C., Neto, E. C., Khan, S. A., Peddinti, G., Airola, A., Pahikkala, T., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30560-5 · Cited by 135
Self-citationAndrogen Receptor Signaling in Prostate Cancer and Therapeutic Strategies
Jacob, A., Raj, R., Allison, D. B., & Myint, Z. W. (2021) · Cancers · doi:10.3390/cancers13215417 · Cited by 158
“77) [9] COU-AA-302 III Abiraterone + ADT Placebo + ADT 1088 Chemo-naïve mCRPC 34.”
BackgroundAdaptation or selection—mechanisms of castration-resistant prostate cancer
Zong, Y., & Goldstein, A. S. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.237 · Cited by 162
Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
Dayyani, F., Gallick, G. E., Logothetis, C. J., & Corn, P. G. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr362 · Cited by 141
Self-citationRuscetti, M. A., Dadashian, E. L., Guo, W., Quach, B., Mulholland, D. J., Park, J. W., Tran, L. M., Kobayashi, N., Bianchi-Frias, D., Xing, Y., et al. (2015) · Oncogene · doi:10.1038/onc.2015.444 · Cited by 136
“2 Treatment of CRPC with new generation androgen signaling inhibitors such as enzalutamide and abiraterone acetate has improved survival outcomes; 3, 4 however, CRPC remains incurable, and patients generally die within 2 years.”
Luo, J., Attard, G., Balk, S. P., Bevan, C. L., Burnstein, K. L., Cato, L., Cherkasov, A. R., Bono, J. S. D., Dong, Y., Gao, A. C., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.11.038 · Cited by 135
“Three thematic topics were predefined prior to the meeting: (1) potential of AR-Vs as biomarkers of therapeutic resistance, (2) role of AR-Vs as functionally active CRPC progression drivers, and (3) utility of AR-Vs as therapeutic targets in CRPC.”
Self-citationSchweizer, M. T., Haugk, K. L., McKiernan, J. S., Gulati, R., Cheng, H. H., Maes, J. L., Dumpit, R. F., Nelson, P. S., Montgomery, B., McCune, J. S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198389 · Cited by 145
Morris, M. J., Molina, A., Small, E. J., de Bono, J. S., Logothetis, C. J., Fizazi, K., de Souza, P., Kantoff, P. W., Higano, C. S., Li, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3875 · Cited by 133
Self-citationZhao, Y., Wang, L., Ren, S., Wang, L., Blackburn, P. R., McNulty, M. S., Gao, X., Qiao, M., Vessella, R. L., Kohli, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.038 · Cited by 133
Neoadjuvant Enzalutamide Prior to Prostatectomy
Montgomery, B., Tretiakova, M., Joshua, A. M., Gleave, M. E., Fleshner, N. E., Bubley, G. J., Mostaghel, E. A., Chi, K. N., Lin, D. W., Sanda, M. G., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1357 · Cited by 143
“Agents that further inhibit androgen synthesis and AR signaling include abiraterone acetate (a direct inhibitor of tissue steroidogenesis and AR antagonist) and enzalutamide (enza), a small-molecule inhibitor of the ligand-binding domain of the AR, AR translocation, and DNA binding (1, 2, 6, 7).”
Self-citationButler, D. E., Marlein, C. R., Walker, H. F., Frame, F. M., Mann, V. M., Simms, M. S., Davies, B. R., Collins, A. T., & Maitland, N. J. (2017) · Oncotarget · doi:10.18632/oncotarget.18082 · Cited by 143
Molecular Pathogenesis and Progression of Prostate Cancer
Schrecengost, R. S., & Knudsen, K. E. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.04.001 · Cited by 159
“Abiraterone treatment effectively decreases growth of PCa bone metastases(60) and is approved by the US Food and Drug Administration for treatment of metastatic PCa patients with prior docetaxel treatment.(61) However, abiraterone treatment is capable of selecting for resistance due to increasing intratumoral levels o…”
BackgroundObjective assessment of cancer genes for drug discovery
Patel, M. N., Halling‐Brown, M., Tym, J. E., Workman, P., & Al‐Lazikani, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3913 · Cited by 149
Emerging mechanisms of enzalutamide resistance in prostate cancer
Claessens, F., Helsen, C., Preković, S., den Broeck, T. V., Spans, L., Poppel, H. V., & Joniau, S. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.243 · Cited by 145
Barber, T. W., Singh, A., Kulkarni, H. R., Niepsch, K., Billah, B., & Baum, R. P. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.216820 · Cited by 132
“OS with these agents as second-line therapies in selected patient cohorts ranges from 14 to 18 mo (4,8,9,11).”
BackgroundThe treatment landscape of metastatic prostate cancer
Yamada, Y., & Beltran, H. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.010 · Cited by 156
Sathianathen, N. J., Konety, B. R., Crook, J. M., Saad, F., & Lawrentschuk, N. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0060-7 · Cited by 168
Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer
Rathkopf, D., & Scher, H. I. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e318282635a · Cited by 129
“Serum androgens are reduced to the 1–2 ng/dl range.11 Notably, abiraterone acetate was the first hormonal agent targeting an oncogenic change in AR signaling proven to prolong life in men with progressive men with CRPC previously treated with docetaxel (Cougar AA-301: NCT00638690) and the first hormonal agent approved…”
BackgroundSelf-citationSalvi, S., Casadio, V., Conteduca, V., Burgio, S. L., Menna, C., Bianchi, E., Rossi, L., Carretta, E., Masini, C., Amadori, D., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.128 · Cited by 135
“A randomised phase III trial of abiraterone vs placebo in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with docetaxel showed a significant increase in progression-free survival (PFS) and overall survival (OS) (de Bono et al, 2011; Fizazi et al, 2012).”
BackgroundTargeting the adaptive molecular landscape of castration‐resistant prostate cancer
Wyatt, A. W., & Gleave, M. E. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201303701 · Cited by 127
“Even those patients that enjoy initial responses will eventually acquire resistance (Scher et al , 2010, 2012; de Bono et al , 2011).”
The role of GATA2 in lethal prostate cancer aggressiveness
Rodríguez-Bravo, V., Carceles‐Cordon, M., Hoshida, Y., Cordon‐Cardo, C., Galsky, M. D., & Domenech, J. M. D. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.225 · Cited by 145
Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer
Gao, S., Chen, S., Han, D. G., Wang, Z., Li, M., Han, W., Besschetnova, A., Liu, M., Zhou, F., Barrett, D. A., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0681-7 · Cited by 138
Androgen receptor splice variants and prostate cancer: From bench to bedside
Wadosky, K. M., & Koochekpour, S. (2017) · Oncotarget · doi:10.18632/oncotarget.14537 · Cited by 150
“It was originally thought that CR-PCa is independent of androgens; however, FDA approval of CR-PCa drugs within the last 5 years that target the androgen axis has eradicated this notion [13, 21-24].”
BackgroundHarshman, L. C., Chen, Y., Liu, G., Carducci, M. A., Jarrard, D. F., Dreicer, R., Hahn, N. M., Garcia, J. A., Hussain, M., Shevrin, D. H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3921 · Cited by 139
“inhibitors such as abiraterone acetate, bone metastasis–homing radiationwith radium-223, and an autologous dendritic cell vaccine sipuleucel-T.(5-12) Given that these drugs yield only incremental survival benefits, attempts to improve the outcomes of this largely fatal disease have evolved to move these agents forward…”
BackgroundRadium-223 mechanism of action: implications for use in treatment combinations
Morris, M. J., Corey, E., Guise, T. A., Gulley, J. L., Kelly, W. K., Quinn, D. I., Scholz, A., & Sgouros, G. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0251-x · Cited by 140
Modern paradigms for prostate cancer detection and management
Williams, I. S. C., McVey, A., Perera, S., O'Brien, J. S., Kostos, L. K., Chen, K. S.-M., Siva, S., Azad, A., Murphy, D. G., Kasivisvanathan, V., et al. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51722 · Cited by 168
Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression.
Grant, C. M., & Kyprianou, N. (2013) · PubMed Central · doi:10.3978/j.issn.2223-4683.2013.09.04 · Cited by 154
“Recently however, abiraterone acetate, a CYP17A1 inhibitor, blocks the synthesis of adrenal androgens and has been FDA-approved to treat CRPC (15).”
BackgroundFriedlander, T. W., Ngo, V., Dong, H., Premasekharan, G., Weinberg, V., Doty, S., Zhao, Q., Gilbert, E., Ryan, C. J., Chen, W., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28561 · Cited by 129
Self-citationSternberg, C. N., Bono, J. S. D., Chi, K. N., Fizazi, K. S., Mulders, P., Cerbone, L., Hirmand, M., Forer, D., & Scher, H. I. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt571 · Cited by 132
Self-citationSteroid sulfatase inhibitors for estrogen- and androgen-dependent cancers
Purohit, A., & Foster, P. A. (2012) · Journal of Endocrinology · doi:10.1530/joe-11-0266 · Cited by 126
“…breast, prostate, and endometrial, initially rely on steroid production for growth: only later in development do they usually become steroid-independent with the exception of prostate cancer which can remain androgen dependent even at late-stage (Knudsen & Penning 2010, de Bono et al. 2011).”
Hoang, D. T., Iczkowski, K. A., Kilari, D., See, W. A., & Nevalainen, M. T. (2016) · Oncotarget · doi:10.18632/oncotarget.12554 · Cited by 144
“Production of androgen precursors, such as dehydroepiandrosterone (DHEA) and androstenedione, is blocked by abiraterone, which inhibits the enzymatic activity of the CYP17A1 enzyme [80, 81].”
BackgroundLipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy
Stoykova, G. E., & Schlaepfer, I. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112626 · Cited by 129
“Several drugs, including improved AR antagonists (enzalutamide) and inhibitors of androgen synthesis (abiraterone), extend survival [83,84], although to date, complete remissions have been rare.”
BackgroundCauses of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016
Elmehrath, A. O., Afifi, A. M., Al‐Husseini, M. J., Saad, A. M., Wilson, N. R., Shohdy, K. S., Pilie, P. G., Sonbol, M. B., & Alhalabi, O. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.19568 · Cited by 142
Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018
Lowrance, W. T., Murad, M. H., Oh, W. K., Jarrard, D. F., Resnick, M. J., & Cookson, M. S. (2018) · The Journal of Urology · doi:10.1016/j.juro.2018.07.090 · Cited by 131
Wu, J. N., Fish, K. M., Evans, C. P., White, R. D., & Dall’Era, M. (2013) · Cancer · doi:10.1002/cncr.28485 · Cited by 128
Péron, J., Maillet, D., Gan, H. K., Chen, E. X., & You, B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3981 · Cited by 125
Li, Y., He, Y., Butler, W., Xu, L., Chang, Y., Lei, K., Zhang, H., Zhou, Y., Gao, A. C., Zhang, Q., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0428 · Cited by 131
“Second-generation hormonal therapy drugs enzalutamide and abiraterone acetate have shown efficacy against CRPC, but resistance still occurs (2, 3).”
BackgroundJames, N. D., Sydes, M. R., Mason, M. D., Clarke, N. W., Anderson, J., Dearnaley, D. P., Dwyer, J., Jovic, G., Ritchie, A. W., Russell, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70088-8 · Cited by 123
Targeting bone metastases in prostate cancer: improving clinical outcome
Body, J., Casimiro, S., & Costa, L. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.90 · Cited by 132
Fred Saad, C., Fizazi, K. S., Jinga, V., Efstathiou, E., Fong, P. C. C., Hart, L. L., Jones, R. J., McDermott, R., Wirth, M. P., Suzuki, K., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70027-6 · Cited by 131
Self-citationGATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex
He, B., Lanz, R. B., Fiskus, W., Geng, C., Yi, P., Hartig, S. M., Rajapakshe, K., Shou, J., Wei, L., Shah, S. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421415111 · Cited by 123
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role
Huang, J., Jochéms, C., Talaie, T., Anderson, A., Jales, A., Tsang, K. Y., Madan, R. A., Gulley, J. L., & Schlom, J. (2012) · Blood · doi:10.1182/blood-2012-05-427799 · Cited by 124
“in about half of the patients in this trial, a proportion of responding patients similar to that seen with docetaxel-based therapy,(24) and abiraterone, a recently approved adrenal steroid inhibitor.(25) For personal use only.”
ResultInhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer
Liu, C., Armstrong, C. M., Lou, W., Lombard, A., Evans, C. P., & Gao, A. C. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0186 · Cited by 119
“Although initially effective, most patients receiving abiraterone will progress in their disease by 15 months of treatment (4).”
BackgroundInfluentialGraff, J. N., Beer, T. M., Alumkal, J. J., Slottke, R., Redmond, W. L., THOMAS, G. V., Thompson, R. F., Wood, M. A., Koguchi, Y., Chen, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000642 · Cited by 127
Watahiki, A., Macfarlane, R. J., Gleave, M. E., Crea, F., Wang, Y. Z., Helgason, C. D., & Chi, K. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14047757 · Cited by 130
“Monitoring expression levels of plasma miRNAs may also be useful as predictive and prognostic biomarkers, particularly those associated with AR signalling, like miR-21, given the recent availability of treatments for mCRPC, like abiraterone acetate [28] and enzalutamide (MDV3100) [29], which target persistent AR signa…”
BackgroundSelf-citationWelti, J. C., Rodrigues, D. N., Sharp, A., Sun, S., Lorente, D., Riisnaes, R., Figueiredo, I., Zafeiriou, Z., Rescigno, P., Bono, J. S. D., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.03.049 · Cited by 132
Fox, J. J., Gavane, S. C., Blanc-Autran, E., Nehmeh, S. A., Gönen, M., Beattie, B., Vargas, H. A., Schöder, H. M., Humm, J. L., Fine, S. W., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3588 · Cited by 126
Self-citationLin, T., Lee, S. O., Niu, Y., Xu, D., Liang, L., Li, L., Yeh, S. D., Fujimoto, N., Yeh, S., & Chang, C. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.477216 · Cited by 127
“The newly developed anti-androgens were able to delay the recurrence (2, 3).”
BackgroundAndrogen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
Gao, L., Schwartzman, J. A., Gibbs, A., Lisac, R., Kleinschmidt, R., Wilmot, B., Bottomly, D., Coleman, I. M., Nelson, P. S., McWeeney, S. K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063563 · Cited by 133
Circulating tumour cells—monitoring treatment response in prostate cancer
Miyamoto, D. T., Sequist, L. V. D., & Lee, R. J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.82 · Cited by 133
Ryan, C. J., Molina, A., Li, J., Kheoh, T. S., Small, E. J., Haqq, C. M., Grant, R. P., Bono, J. S. D., & Scher, H. I. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.4595 · Cited by 128
“Primary results were reported previously.(5) Ninety percent of patients entering the study had bone metastases and 30% had visceral metastatic disease.”
BackgroundSelf-citationEtchebehere, E., Araujo, J. C., Fox, P. S., Swanston, N. M., Macapinlac, H. A., & ROHREN, E. M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.158626 · Cited by 126
“Since chemotherapy and hormonal therapy has improved OS of prostate cancer patients with visceral metastases, (37),(38),(39, 40) our patients with visceral metastases were treated with combination Ra-223 and chemotherapy (cyclophosphamide (6 pts), paclitaxel (3 pts), doxorubicin (1 pt), docetaxel (1 pt) and mitoxantro…”
BackgroundLi, H., Ban, F., Dalal, K., Leblanc, E., Frewin, K., Ma, D., Adomat, H., Rennie, P. S., & Cherkasov, A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500802j · Cited by 119
Fizazi, K., & Gillessen, S. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.02.015 · Cited by 119
Self-citationStructures of human steroidogenic cytochrome P450 17A1 with substrates
Petrunak, E. M., DeVore, N. M., Porubsky, P. R., & Scott, E. E. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.610998 · Cited by 119
“Abiraterone acetate, the Food and Drug Administration-approved prodrug form of this CYP17A1 inhibitor, improves overall survival in men with metastatic castration-resistant prostate cancer, including patients for whom the disease has progressed following chemotherapy, with compounds such as docetaxel and the androgen…”
BackgroundTucci, M., Bertaglia, V., Vignani, F., Buttigliero, C., Fiori, C., Porpiglia, F., Scagliotti, G. V., & Maïo, M. D. (2015) · European Urology · doi:10.1016/j.eururo.2015.09.013 · Cited by 131
“Results from RCTs have demonstrated the efficacy of two new-generation hormonal therapies (abiraterone [8] and enzalutamide [9]), an immunotherapy (sipuleucel-T [10]), a new microtubuletargeting chemotherapy (cabazitaxel [11]), and an aemitter (radium-223 [12]), all able to prolong OS.”
Backgroundde Bono, J. S., Chowdhury, S., Feyerabend, S., Elliott, T., Grande, E., Melhem-Bertrandt, A., Baron, B., Hirmand, M., Werbrouck, P., & Fizazi, K. (2018) · European Urology · doi:10.1016/j.eururo.2017.07.035 · Cited by 119
Self-citationProstate cancer sheds the αvβ3 integrin in vivo through exosomes
Krishn, S. R., Singh, A., Bowler, N., Duffy, A. N., Friedman, A., Fedele, C., Kurtoglu, S., Tripathi, S., Wang, K., Hawkins, A., et al. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.08.004 · Cited by 126
CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation
Rasool, R. U., Natesan, R., Deng, Q., Aras, S., Lal, P., Effron, S. S., Mitchell-Velasquez, E., Posimo, J. M., Carskadon, S. L., Baca, S. C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0189 · Cited by 133
Past, Current, and Future of Immunotherapies for Prostate Cancer
Boettcher, A. N., Usman, A., Morgans, A., VanderWeele, D. J., Sosman, J. A., & Wu, J. D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00884 · Cited by 121
Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone
Nakazawa, M., Antonarakis, E. S., & Luo, J. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0190-1 · Cited by 132
“In the last decade, a variety of other therapies have been approved or are in development, the most notable of which are abiraterone and enzalutamide, two FDAapproved AR-targeted therapies demonstrating significant improvement in survival in the CRPC setting (both before and after docetaxel use) [77, 24, 7, 70].”
BackgroundBrasso, K., Thomsen, F. B., Schrader, A. J., Schmid, S. C., Lorente, D., Retz, M. M., Merseburger, A. S., von Klot, C. A., Boegemann, M., & Bono, J. S. D. (2014) · European Urology · doi:10.1016/j.eururo.2014.07.028 · Cited by 121
“…castration-resistant prostate cancer (mCRPC) during the past decade has provided several effective new therapeutic strategies, including two different taxanes, a systemic alpha particle–emitting radionuclide, as well as two novel endocrine drugs and a vaccine [1] [2] [3] [4] [5] [6] [7] [8].”
BackgroundKiss, B. M., Wyatt, A. W., Douglas, J., Skuginna, V., Mo, F., Anderson, S. A., Rotzer, D., Fleischmann, A., Genitsch, V., Hayashi, T., et al. (2017) · Scientific Reports · doi:10.1038/srep42713 · Cited by 124
Steroid biosynthesis and prostate cancer
Sharifi, N., & Auchus, R. J. (2012) · Steroids · doi:10.1016/j.steroids.2012.03.015 · Cited by 116
“Over the last 4 years, the therapeutic efficacy of abiraterone acetate, a 17a-hydroxylase/ 17,20-lyase (CYP17A1) inhibitor, confirmed that CRPC continues to be driven by AR activation [12].”
BackgroundTreatment of mCRPC in the AR-axis-targeted therapy-resistant state
Chi, K. N., Hotte, S. J., Joshua, A. M., North, S. A., Wyatt, A. W., Collins, L. L., & Fred Saad, C. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv267 · Cited by 123
“Although abiraterone, enzalutamide, and cabazitaxel have all demonstrated activity as second-line treatment for mCRPC in docetaxel-pretreated patient populations [15, 18, 87], their role in chemotherapy-naïve, ARAT therapy-pretreated populations is less clear.”
BackgroundSelf-citationThe Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
Patel, P. H., Palma, D. A., McDonald, F., & Tree, A. C. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.05.015 · Cited by 119
Nelson, J. B., Fizazi, K., Miller, K., Higano, C., Moul, J. W., Akaza, H., Morris, T., McIntosh, S., Pemberton, K., & Gleave, M. (2012) · Cancer · doi:10.1002/cncr.27674 · Cited by 114
Self-citationGui, B., Gui, F., Takai, T., Feng, C., Bai, X., Fazli, L., Dong, X., Liu, S., Zhang, X., Zhang, W., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908547116 · Cited by 115
Wang, Y., Chen, J., Wu, Z., Ding, W., Gao, S., Gao, Y., & Xu, C. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15300 · Cited by 125
Penning, T. M. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.07.002 · Cited by 117
Yamaoka, M., Hara, T., Hitaka, T., Kaku, T., Takeuchi, T., Takahashi, J., Asahi, S., Miki, H., Tasaka, A., & Kusaka, M. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.01.001 · Cited by 123
Harrison, M. R., George, D. J., Wong, & Armstrong, A. J. (2013) · Cancer Management and Research · doi:10.2147/cmar.s25537 · Cited by 130
“Patients treated with abiraterone acetate have demonstrated side effects related to mineralocorticoid excess due to the drug’s mechanism of action, such as fluid retention, hypertension, and hypokalemia.(14) The most common side effect overall and grade 3 or 4 side effect observed with”
BackgroundYadav, M. P., Ballal, S., Bal, C., Sahoo, R. K., Damle, N. A., Tripathi, M., & Seth, A. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002833 · Cited by 122
“Similarly, a number of phase III trials demonstrating improvement in OS and progressionfree survival have led to the introduction of novel androgen therapies such as abiraterone acetate (AA) and enzalutamide.(7,8) They offer mCRPC patients as both first- and second-line therapy options in chemotherapy-refractory patie…”
BackgroundOvercoming Drug Resistance and Treating Advanced Prostate Cancer
Semenas, J., Allegrucci, C., Boorjian, S. A., Mongan, N. P., & Persson, J. L. (2012) · Current Drug Targets · doi:10.2174/138945012802429615 · Cited by 125
Adrenal Androgens and Androgen Precursors-Definition, Synthesis, Regulation and Physiologic Actions
Turcu, A., Smith, J. M., Auchus, R., & Rainey, W. E. (2014) · Comprehensive physiology · doi:10.1002/cphy.c140006 · Cited by 113
“New drugs targeting CYP17A1 (like abiraterone acetate) block this “backdoor pathway” and prolong survival for men with CRPC with or without prior docetaxel treatment (37, 146).”
Isaacs, J. T., D’Antonio, J. M., Chen, S., Antony, L., Dalrymple, S. P., Ndikuyeze, G. H., Luo, J., & Denmeade, S. R. (2012) · The Prostate · doi:10.1002/pros.22504 · Cited by 113
“, <5 months) increases in median survival [3].”
BackgroundInfluentialZhong, J., Ding, L., Bohrer, L. R., Pan, Y., Liu, P., Zhang, J., Sebo, T. J., Karnes, R. J., Tindall, D. J., van Deursen, J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2485 · Cited by 115
“The importance of persistent AR signaling in CRPC is further demonstrated by the antitumor activity of next-generation androgen-AR axis inhibitors including abiraterone and enzalutamide (4, 5).”
PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
Velho, P. I., & Antonarakis, E. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1464388 · Cited by 121
“Even after several advances in the last decade, with the approval of numerous medications which demonstrated overall survival (OS) improvements (docetaxel [7], sipuleucel-T [8], cabazitaxel [9] abiraterone [10], enzalutamide [11], and radium-223 [12]), median OS still averages 2–3 years after the tumor becomes resista…”
BackgroundFitzgerald, K. A., Guo, J., Tierney, E. G., Curtin, C. M., Malhotra, M., Darcy, R., O’Brien, F. J., & O’Driscoll, C. M. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.07.019 · Cited by 124
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Strategies for modern biomarker and drug development in oncology
Smith, A. D., Roda, D., & Yap, T. A. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0070-8 · Cited by 116
“More recently, circulating tumor cells (CTCs) have been evaluated as a surrogate biomarker in a number of cancers, including castration-resistant prostate cancer (CRPC), lung, breast and colon cancer [51-59].”
BackgroundNeuroendocrine tumors of the prostate
Fine, S. W. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.164 · Cited by 111
Westdorp, H., Creemers, J. H. A., van Oort, I. M., Schreibelt, G., Gorris, M. A. J., Mehra, N., Simons, M., de Goede, A. L., van Rossum, M. M., Croockewit, A. J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0787-6 · Cited by 112
A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer
Bai, S., Cao, S., Jin, L., Kobelski, M. M., Schouest, B., Wang, X., Ungerleider, N., Baddoo, M., Zhang, W., Corey, E., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0768-8 · Cited by 135
Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
Auchus, R. J., Yu, M. K., Nguyen, S., & Mundle, S. D. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0167 · Cited by 119
Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment
Amaral, T. M. S., Macedo, D., Fernandes, I., & Costa, L. (2012) · Prostate Cancer · doi:10.1155/2012/327253 · Cited by 133
“The adverse events more frequently related to abiraterone acetate than to placebo group were urinary tract infections, adverse events associated with elevated mineralocorticoid levels such as fluid retention and edema, hypokalemia, and hypertension, as well as cardiac disorders and liver-function test abnormalities [2…”
BackgroundCastration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment
Mansinho, A., Macedo, D., Fernandes, I., & Costa, L. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-99286-0_7 · Cited by 120
Recommandations en onco-urologie 2016-2018 du CCAFU : Cancer de la prostate
Rozet, F., Hennequin, C., Beauval, J., Beuzeboc, P., Cormier, L., Fromont, G., Mongiat-Artus, P., Ouzzane, A., Ploussard, G., Azria, D., et al. (2016) · The French Journal of Urology · doi:10.1016/s1166-7087(16)30705-9 · Cited by 123
Benoist, G. E., Hendriks, R. J., Mulders, P., Gerritsen, W. R., Somford, D. M., Schalken, J. A., van Oort, I. M., Burger, D. M., & van Erp, N. P. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0403-6 · Cited by 109
Metadata
- Authors
- de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., Staffurth, J. N., Mainwaring, P., Harland, S., Flaig, T. W., Hutson, T. E., Cheng, T., Patterson, H., Hainsworth, J. D., Ryan, C. J., Sternberg, C. N., Ellard, S. L., Fléchon, A., Saleh, M., Scholz, M., Efstathiou, E., Zivi, A., Bianchini, D., Loriot, Y., Chieffo, N., Kheoh, T., Haqq, C. M., & Scher, H. I.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Institut Gustave Roussy (FR)
- Cross Cancer Institute (CA)
- BC Cancer Agency (CA)
- University of Glasgow (GB)
- Institute of Cancer Research (GB)
- Velindre Cancer Centre (GB)
- University College London (GB)
- University of Colorado Cancer Center (US)
- University of Calgary (CA)
- University of California, San Francisco (US)
- Azienda Ospedaliera San Camillo-Forlanini (IT)
- Centre Léon Bérard (FR)
- Georgia Cancer Specialists (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Logothetis, Christopher J.
- Molina, Arturo
- Fizazi, Karim
- North, Scott
- Chi, Kim N.
- Jones, Robert J.
- Goodman, Oscar B.
- Staffurth, John N.
- Mainwaring, Paul
- Flaig, Thomas W.
- Hutson, Thomas E.
- Cheng, Tina
- Hainsworth, John D.
- Ryan, Charles J.
- Sternberg, Cora N.
- Ellard, Susan L.
- Fléchon, Aude
- Saleh, Mansoor
- Efstathiou, Eleni
- Bianchini, Diletta
- Loriot, Yohann
- Kheoh, Thian
- Haqq, Christopher M.
- Scher, Howard I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-26
- Volume
- 364
- Issue
- 21
- Pages
- 1995-2005
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3471149
- OpenAlex
- W2110534364
- Cited by
- 4,407
- References
- 54
- Citations by year
- 2026: 111 · 2025: 184 · 2024: 187 · 2023: 209 · 2022: 235 · 2021: 287 · 2020: 290 · 2019: 299 · 2018: 332 · 2017: 322 · 2016: 342 · 2015: 352 · 2014: 384 · 2013: 403 · 2012: 347
- FWCI
- 336.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- Prostate Cancer Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Exelixis
- Les Laboratories Pierre Fabre
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- National Institute for Health and Care Research
- Astellas Pharma
- Genentech
- Foundation Medicine
- Medical Research Council
- National Cancer Institute (P50CA092629)
- Cilag
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- abiraterone, metastatic castration-resistant prostate cancer, androgen biosynthesis inhibition, overall survival, docetaxel, prednisone, prostate-specific antigen progression, progression-free survival, fluid retention, hypokalemia, hypertension
- MeSH terms
- Aged, Androgen Antagonists, Androgens, Androstenes, Androstenols, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Fatigue, Humans, Male, Middle Aged, Neoplasm Metastasis, Prednisone, Prostatic Neoplasms, Steroid 17-alpha-Hydroxylase, Survival Analysis, Treatment Outcome, Disease Progression, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.